Olivier Bylicki

8PUBLICATIONS
33CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 03, 2026
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.

|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

Tina Cascone, Laura Bonanno, Florian Guisier

|Feb 24, 2022
ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.

Sébastien Gendarme, Olivier Bylicki, Christos Chouaid

|Jul 02, 2020
Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.

Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié

|Jan 11, 2020
Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01).

Alain Vergnenègre, Victor Basse, Gwenaelle Le Garff

|Sep 02, 2019
Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care.

Olivier Bylicki, Morgane Didier, Frederic Riviere

Pageof 2

Frequent Collaborators

2 joint publications

Christos Chouaïd

2 joint publications

Florian Guisier

1 joint publications

Alain Vergnenègre

1 joint publications

Jean-Bernard Auliac